Purchase this article with an account.
Elijah Moon, Mehran Taban, Ben Sharareh, Josh Wallsh, Ron P. Gallemore; Monthly versus PRN Ranibizumab for Neovascular AMD: A Randomized Phase 2 Open-Label Study. Invest. Ophthalmol. Vis. Sci. 2011;52(14):133.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To assess efficacy of as needed (pro re nata, PRN) dosing of Ranibizumab versus monthly dosing of Ranibizumab for patients with wet age-related macular degeneration (AMD).
A randomized, controlled clinical single-center trial comparing the efficacy of monthly versus PRN dosing of Ranibizumab (0.5 mg or 2.0 mg) for patients with wet AMD. High-resolution optical coherence tomography (HR-OCT) studies were used to guide PRN treatment and any cystic spaces or subretinal fluid prompted retreatment.
At 12 months, patients receiving PRN Ranibizumab had a mean increase in VA of 7.9 Early Treatment Diabetic Retinopathy Study (ETDRS) letters ± 1.1 standard error and a reduction of central macular thickness on HR-OCT of 58.3 microns ± 8.7 standard error (n = 40). Patients receiving monthly Ranibizumab had a mean increase in VA of 5.2 ETDRS letters ± 3.1 standard error and a reduction of central macular thickness on HR-OCT of 88.1 microns ± 19.4 standard error (n=30). Macular function assessed with multifocal ERG testing and microperimetry improved comparably in both the PRN and monthly groups.
PRN dosing of Ranibizumab guided by HR-OCT appeared to maintain vision and improve macular function, but monthly dosing elicited a greater mean reduction in central macular thickness in wet AMD patients.
Clinical Trial: :
This PDF is available to Subscribers Only